Active Ingredient History
Lisdexamfetamine (LDX) is a d-amphetamine (d-AMPH) pro-drug used to treat Attention Deficit and Hyperactivity Disorder (ADHD) and Binge Eating Disorder (BED). After oral administration, lisdexamfetamine dimesylate is rapidly absorbed from the gastrointestinal tract and converted to dextroamphetamine, which is responsible for the drug’s activity. Amphetamines are thought to block the reuptake of norepinephrine and dopamine into the presynaptic neuron and increase the release of these monoamines into the extraneuronal space. Most common adverse reactions in children, adolescents and/or adults with ADHD were anorexia, anxiety, decreased appetite, decreased weight, diarrhea, dizziness, dry mouth, irritability, insomnia, nausea, upper abdominal pain, and vomiting. Agents that alter urinary pH can alter blood levels of amphetamine. Acidifying agents decrease amphetamine blood levels, while alkalinizing agents increase amphetamine blood levels. Needs to adjust Lisdexamfetamine dosage accordingly. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Amphetamine-Related Disorders (Phase 2)
Anxiety Disorders (Phase 4)
Autism Spectrum Disorder (Phase 4)
Behavior, Addictive (Phase 2)
Binge-Eating Disorder (Phase 3)
Bipolar Disorder (Phase 4)
Brain Diseases (Phase 4)
Brain Injuries, Traumatic (Phase 4)
Bulimia Nervosa (Phase 2)
Cocaine-Related Disorders (Phase 2)
Cognition (Phase 4)
Cognitive Dysfunction (Phase 4)
Deficiency Diseases (Phase 4)
Depression (Phase 3)
Depressive Disorder, Major (Phase 4)
Drug Users (Phase 1)
Fatigue Syndrome, Chronic (Phase 4)
Feeding and Eating Disorders (Phase 2/Phase 3)
Glucose Intolerance (Phase 4)
Healthy Volunteers (Phase 1)
Lisdexamfetamine Dimesylate (Phase 4)
Menopause (Phase 4)
Methamphetamine (Phase 2)
Mood Disorders (Phase 2)
Multiple Sclerosis (Phase 2)
Obesity (Phase 4)
Pediatric Obesity (Early Phase 1)
Salpingo-oophorectomy (Phase 4)
Schizophrenia (Phase 3)
Sleep Deprivation (Phase 2)
Substance-Related Disorders (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
